Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
Adult, ages 18+.
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
